XML 21 R11.htm IDEA: XBRL DOCUMENT
v3.22.2.2

STOCK COMPENSATION | 12 Months Ended
--- | ---
Dec. 31, 2021
Share-based Payment Arrangement [Abstract] |
STOCK COMPENSATION | STOCK COMPENSATION The Company maintains the 2016 Omnibus Incentive Plan (the “Plan”) under which it may grant non-qualified stock options (“NQSOs”), incentive stock options, restricted stock, RSUs and stock appreciation rights, collectively referred to as “Awards.” Awards are granted at exercise prices that are equal to the closing stock price on the date of grant. The Company authorized grants under the Plan of 25 million shares of common stock, plus any unexercised portion of canceled or terminated stock options granted under the legacy DENTSPLY International Inc. 2010 and 2002 Equity Incentive Plans, as amended, and under the legacy Sirona Dental Systems, Inc. 2015 and 2006 Equity Incentive Plans, as amended. Each restricted stock and RSU issued is counted as a reduction of 3.09 shares of common stock available to be issued under the Plan. No key employee may be granted awards in excess of 1 million shares of common stock in any calendar year. The number of shares available for grant under the 2016 Plan at December 31, 2021 is 20 million. The amounts of stock compensation expense recorded in the Company’s Consolidated Statements of Operations for the years ended December 31, 2021, 2020 and 2019 were as follows:
|  | Year Ended December 31,
(in millions) |  | 2021 |  | 2020 |  | 2019
Cost of products sold |  | $ | 3 |  |  | $ | 1 |  |  | $ | 2 |
Selling, general, and administrative expense |  | 44 |  |  | 44 |  |  | 61 |
Research and development expense |  | 2 |  |  | 1 |  |  | 2 |
Total stock based compensation expense |  | $ | 49 |  |  | $ | 46 |  |  | $ | 65 |
Related deferred income tax benefit |  | $ | 6 |  |  | $ | 5 |  |  | $ | 8 |
The Company uses the Black-Scholes option-pricing model to estimate the fair value of each option awarded. The average assumptions used to determine compensation cost for the Company’s NQSOs issued were as follows:
|  | Year Ended December 31,
|  | 2021 |  | 2020 |  | 2019
Weighted average fair value per share |  | $ | 15.90 |  |  | $ | 10.03 |  |  | $ | 12.20 |
Expected dividend yield |  | 0.68 | % |  | 0.84 | % |  | 0.71 | %
Risk-free interest rate |  | 0.79 | % |  | 0.77 | % |  | 2.36 | %
Expected volatility |  | 31.5 | % |  | 24.0 | % |  | 22.6 | %
Expected life (years) |  | 5.08 |  | 5.49 |  | 6.00
The total intrinsic value of options exercised for the years ended December 31, 2021, 2020 and 2019 was $16 million, $3 million and $37 million, respectively. The total fair value of shares vested for the years ended December 31, 2021, 2020 and 2019 was $76 million, $54 million and $44 million, respectively. The NQSO transactions for the year ended December 31, 2021 were as follows:
|  | Outstanding |  | Exercisable
(in millions, except per share amounts) |  | Shares |  | Weighted Average Exercise Price |  | Aggregate Intrinsic Value |  | Shares |  | Weighted Average Exercise Price |  | Aggregate Intrinsic Value
December 31, 2020 |  | 4.0 |  |  | $ | 50.01 |  |  | $ | 17 |  |  | 2.7 |  |  | $ | 50.28 |  |  | $ | 12 |
Granted |  | 0.5 |  |  | 58.85 |  |  |  |  |  |  |  |  |
Exercised |  | (1.1) |  |  | 46.81 |  |  |  |  |  |  |  |  |
Forfeited |  | (0.2) |  |  | 53.03 |  |  |  |  |  |  |  |  |
December 31, 2021 |  | 3.2 |  |  | $ | 52.44 |  |  | $ | 15 |  |  | 2.2 |  |  | $ | 52.05 |  |  | $ | 11 |
There were 1.0 million NQSOs unvested at December 31, 2021. The remaining unamortized compensation cost related to NQSOs is $9 million, which will be expensed over the weighted average remaining vesting period of the options, or 1.8 years. The weighted average remaining contractual term of all outstanding options is 5.6 years and the weighted average remaining contractual term of exercisable options is 4.2 years. Information about NQSOs outstanding for the year ended December 31, 2021 were as follows:
|  |  |  | Outstanding |  | Exercisable
|  | Number Outstanding at December 31, 2021 |  | Weighted Average Remaining Contractual Life (in years) |  | Weighted Average Exercise Price |  | Number Exercisable at December 31, 2021 |  | Weighted Average Exercise Price
Range of Exercise Prices |  |  |  |  |
(in millions, except per share amounts and life) |  |  |  |  |
30.01 |  | - | 40.00 |  | 0.1 |  |  | 1.4 |  | $ | 37.29 |  |  | 0.1 |  |  | $ | 37.29 |
40.01 |  | - | 50.00 |  | 1.4 |  |  | 5.9 |  | 47.31 |  |  | 0.8 |  |  | 46.73 |
50.01 |  | - | 60.00 |  | 1.4 |  |  | 6.0 |  | 56.32 |  |  | 0.9 |  |  | 55.05 |
60.01 |  | - | 70.00 |  | 0.3 |  |  | 4.3 |  | 62.37 |  |  | 0.4 |  |  | 62.24 |
|  |  |  | 3.2 |  |  |  |  |  |  | 2.2 |  |  |
The unvested RSU transactions for the year ended December 31, 2021 were as follows:
|  | Unvested Restricted Stock Units
|  | Shares |  | Weighted Average Grant Date Fair Value
(in millions, except per share amounts) |  |
Unvested at December 31, 2020 |  | 4.2 |  |  | $ | 47.29 |
Granted |  | 1.0 |  |  | 63.61 |
Vested |  | (1.5) |  |  | 45.08 |
Forfeited |  | (0.6) |  |  | 50.01 |
Unvested at December 31, 2021 |  | 3.1 |  |  | $ | 53.52 |
The unamortized compensation cost related to RSUs is $42 million, which will be expensed over the remaining weighted average restricted period of the RSUs, or 2.0 years.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration